94 related articles for article (PubMed ID: 30263935)
1. Regulation of protein metabolism in cancer.
Han C; Lu X; Nagrath D
Mol Cell Oncol; 2018; 5(5):e1285384. PubMed ID: 30263935
[TBL] [Abstract][Full Text] [Related]
2. Amplification of USP13 drives ovarian cancer metabolism.
Han C; Yang L; Choi HH; Baddour J; Achreja A; Liu Y; Li Y; Li J; Wan G; Huang C; Ji G; Zhang X; Nagrath D; Lu X
Nat Commun; 2016 Nov; 7():13525. PubMed ID: 27892457
[TBL] [Abstract][Full Text] [Related]
3. CK2-Mediated Phosphorylation Upregulates the Stability of USP13 and Promotes Ovarian Cancer Cell Proliferation.
Kwon J; Zhang J; Mok B; Han C
Cancers (Basel); 2022 Dec; 15(1):. PubMed ID: 36612196
[TBL] [Abstract][Full Text] [Related]
4. ATP citrate lyase (ACLY) inhibitors: An anti-cancer strategy at the crossroads of glucose and lipid metabolism.
Granchi C
Eur J Med Chem; 2018 Sep; 157():1276-1291. PubMed ID: 30195238
[TBL] [Abstract][Full Text] [Related]
5. ATP citrate lyase: A central metabolic enzyme in cancer.
Icard P; Wu Z; Fournel L; Coquerel A; Lincet H; Alifano M
Cancer Lett; 2020 Feb; 471():125-134. PubMed ID: 31830561
[TBL] [Abstract][Full Text] [Related]
6. Polyamine regulating protein antizyme binds to ATP citrate lyase to accelerate acetyl-CoA production in cancer cells.
Tajima A; Murai N; Murakami Y; Iwamoto T; Migita T; Matsufuji S
Biochem Biophys Res Commun; 2016 Mar; 471(4):646-51. PubMed ID: 26915799
[TBL] [Abstract][Full Text] [Related]
7. ATP citrate lyase (ACLY): a promising target for cancer prevention and treatment.
Khwairakpam AD; Shyamananda MS; Sailo BL; Rathnakaram SR; Padmavathi G; Kotoky J; Kunnumakkara AB
Curr Drug Targets; 2015; 16(2):156-63. PubMed ID: 25537655
[TBL] [Abstract][Full Text] [Related]
8. miR-22 inhibits tumor growth and metastasis by targeting ATP citrate lyase: evidence in osteosarcoma, prostate cancer, cervical cancer and lung cancer.
Xin M; Qiao Z; Li J; Liu J; Song S; Zhao X; Miao P; Tang T; Wang L; Liu W; Yang X; Dai K; Huang G
Oncotarget; 2016 Jul; 7(28):44252-44265. PubMed ID: 27317765
[TBL] [Abstract][Full Text] [Related]
9. Role of USP13 in physiology and diseases.
Wang Q; Sun Z; Xia W; Sun L; Du Y; Zhang Y; Jia Z
Front Mol Biosci; 2022; 9():977122. PubMed ID: 36188217
[TBL] [Abstract][Full Text] [Related]
10. Cullin3-KLHL25 ubiquitin ligase targets ACLY for degradation to inhibit lipid synthesis and tumor progression.
Zhang C; Liu J; Huang G; Zhao Y; Yue X; Wu H; Li J; Zhu J; Shen Z; Haffty BG; Hu W; Feng Z
Genes Dev; 2016 Sep; 30(17):1956-70. PubMed ID: 27664236
[TBL] [Abstract][Full Text] [Related]
11. Inhibition of ATP citrate lyase induces triglyceride accumulation with altered fatty acid composition in cancer cells.
Migita T; Okabe S; Ikeda K; Igarashi S; Sugawara S; Tomida A; Soga T; Taguchi R; Seimiya H
Int J Cancer; 2014 Jul; 135(1):37-47. PubMed ID: 24310723
[TBL] [Abstract][Full Text] [Related]
12. Inhibition of mitochondrial 2-oxoglutarate dehydrogenase impairs viability of cancer cells in a cell-specific metabolism-dependent manner.
Bunik VI; Mkrtchyan G; Grabarska A; Oppermann H; Daloso D; Araujo WL; Juszczak M; Rzeski W; Bettendorff L; Fernie AR; Meixensberger J; Stepulak A; Gaunitz F
Oncotarget; 2016 May; 7(18):26400-21. PubMed ID: 27027236
[TBL] [Abstract][Full Text] [Related]
13. ACLY (ATP Citrate Lyase) Mediates Radioresistance in Head and Neck Squamous Cell Carcinomas and is a Novel Predictive Radiotherapy Biomarker.
Göttgens EL; van den Heuvel CN; de Jong MC; Kaanders JH; Leenders WP; Ansems M; Bussink J; Span PN
Cancers (Basel); 2019 Dec; 11(12):. PubMed ID: 31817870
[TBL] [Abstract][Full Text] [Related]
14. ATP-citrate lyase: genetics, molecular biology and therapeutic target for dyslipidemia.
Burke AC; Huff MW
Curr Opin Lipidol; 2017 Apr; 28(2):193-200. PubMed ID: 28059952
[TBL] [Abstract][Full Text] [Related]
15. ATP-citrate lyase: a key player in cancer metabolism.
Zaidi N; Swinnen JV; Smans K
Cancer Res; 2012 Aug; 72(15):3709-14. PubMed ID: 22787121
[TBL] [Abstract][Full Text] [Related]
16. ATP-citrate lyase regulates cellular senescence via an AMPK- and p53-dependent pathway.
Lee JH; Jang H; Lee SM; Lee JE; Choi J; Kim TW; Cho EJ; Youn HD
FEBS J; 2015 Jan; 282(2):361-71. PubMed ID: 25367309
[TBL] [Abstract][Full Text] [Related]
17. Prognostic impact of the combination of glucose transporter 1 and ATP citrate lyase in node-negative patients with non-small lung cancer.
Osugi J; Yamaura T; Muto S; Okabe N; Matsumura Y; Hoshino M; Higuchi M; Suzuki H; Gotoh M
Lung Cancer; 2015 Jun; 88(3):310-8. PubMed ID: 25837797
[TBL] [Abstract][Full Text] [Related]
18. Decreased Warburg effect induced by ATP citrate lyase suppression inhibits tumor growth in pancreatic cancer.
Zong H; Zhang Y; You Y; Cai T; Wang Y
Med Oncol; 2015 Mar; 32(3):85. PubMed ID: 25701462
[TBL] [Abstract][Full Text] [Related]
19. Polarization of Human Macrophages by Interleukin-4 Does Not Require ATP-Citrate Lyase.
Namgaladze D; Zukunft S; Schnütgen F; Kurrle N; Fleming I; Fuhrmann D; Brüne B
Front Immunol; 2018; 9():2858. PubMed ID: 30568658
[TBL] [Abstract][Full Text] [Related]
20. ATP-citrate lyase is essential for macrophage inflammatory response.
Infantino V; Iacobazzi V; Palmieri F; Menga A
Biochem Biophys Res Commun; 2013 Oct; 440(1):105-11. PubMed ID: 24051091
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
